• SPX
  • $5,926.15
  • 0.15 %
  • $9.04
  • DJI
  • $43,781.17
  • 0.86 %
  • $372.69
  • N225
  • $38,026.17
  • -0.85 %
  • -$326.17
  • FTSE
  • $8,151.19
  • 0.82 %
  • $66.12
  • IXIC
  • $18,879.49
  • -0.46 %
  • -$86.65
Viatris Inc. (VTRS) Stock Price, News & Analysis

Viatris Inc. (VTRS) Stock Price, News & Analysis

Currency in USD Disclaimer

$13.23

$0.1

(0.72%)

Day's range
$13.1
Day's range
$13.24
50-day range
$11.19
Day's range
$13.44
  • Country: US
  • ISIN: US92556V1061
52 wk range
$9.08
Day's range
$13.62


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 0.92
  • Piotroski Score 5.00
  • Grade Neutral
  • Symbol (VTRS)
  • Company Viatris Inc.
  • Price $13.23
  • Changes Percentage (0.72%)
  • Change $0.1
  • Day Low $13.10
  • Day High $13.24
  • Year High $13.62

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

  • Last Earnings 11/04/2024
  • Ex-Dividend for 5/16 Dividend 11/22/2024
  • Dividend Payable 12/13/2024
  • Today N/A
  • Next Earnings (Estimated) 02/26/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $14.00
  • High Stock Price Target $15.00
  • Low Stock Price Target $12.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.05
  • Trailing P/E Ratio -209.4
  • Forward P/E Ratio -209.4
  • P/E Growth -209.4
  • Net Income $54.70 M

Income Statement

Quarterly

Annual

Latest News of VTRS

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Viatris Inc. Frequently Asked Questions

  • What were the earnings of VTRS in the last quarter?

    In the last quarter Viatris Inc. earnings were on Thursday, November, 7th. The Viatris Inc. maker reported $0.75 EPS for the quarter, beating analysts' consensus estimates of $0.68 by $0.07.

  • What is the Viatris Inc. stock price today?

    Today's price of Viatris Inc. is $13.23 — it has increased by +0.72% in the past 24 hours. Watch Viatris Inc. stock price performance more closely on the chart.

  • Does Viatris Inc. release reports?

    Yes, you can track Viatris Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Viatris Inc. stock forecast?

    Watch the Viatris Inc. chart and read a more detailed Viatris Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Viatris Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Viatris Inc. stock ticker.

  • How to buy Viatris Inc. stocks?

    Like other stocks, VTRS shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Viatris Inc.'s EBITDA?

    Viatris Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Viatris Inc.’s financial statements.

  • What is the Viatris Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0.0035457545, which equates to approximately 0.35%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Viatris Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Viatris Inc.'s financials relevant news, and technical analysis. Viatris Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Viatris Inc. stock currently indicates a “sell” signal. For more insights, review Viatris Inc.’s technical analysis.

  • A revenue figure for Viatris Inc. for its last quarter?

    Viatris Inc. published it's last quarterly revenues at $3.74 B.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.